drugset / Trial / NCT00940017

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

NCT00940017

Phase 4 Completed 24 enrolled Pfizer
RandomizedSingle-groupOpen-label

Summary

The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.

Timeline

Start
2008-09
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Anidulafungin Other / unclassified 100 mg Intravenous
Subject Voriconazole Small molecule 4 mg/kg Intravenous